Latest filing published 07 Oct 2026 for UCB, €20k. Read the official filing
Based on 13 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Castella Maelys in UCB, where the filings describe the role as board member. Between 30 September 2025 and 5 October 2026, the trades on record add up to 14 filings.
No open-market sale appears; the market trades are 14 purchases worth €267k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €15k. 11 out of 14 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 13 purchases show a median change of +20.5%, with the price up in 85% of them. They describe history only and say nothing certain about the share price ahead.
The latest filing, published on 7 October 2026, reports an open-market purchase of €20k in UCB. Typically, a trade is published a median of 6 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by FSMA and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations